Artiva Biotherapeutics (ARTV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Good morning, everyone. Thank you for attending Jefferies Healthcare Conference. My name is Kelly Xu, one of the equity analysts here on the biotech team. We are very pleased to have Doctor. Fred Aslan, CEO of Ativa Biotherapeutics join us today. Welcome, Fred. Speaker1 Thank you, Kelly. Speaker0 And maybe let's first start with a big picture question. Many cell therapies in the autoimmune space originated from oncology and Ati ...

Paylocity (PCTY) FY Conference June 04, 2025 09:20 AM ET Speaker0 Both in person and listening over the webcast. Before we kick things off, my name is Jacob Behrge. I am the the research analyst here at William Blair, that covers Paylocity. And so for a full list of our research disclosures, please visit our website at WilliamBlair.com. But with that, really excited to have Ryan Glenn here, chief financial officer of Paylocity. Thanks thanks for joining us today, Ryan. Speaker1 Appreciate it. Thanks for hav ...

Nayax (NYAX) FY Conference June 04, 2025 09:00 AM ET Speaker0 Good morning, everyone. Welcome to day two of the William Blair Annual Growth Stock Conference. This is the forty fifth edition. We appreciate you attending both in person and online. My name is Chris Kennedy. I'm the research analyst at William Blair who covers the fintech and payment space. For a complete list of research disclosures and or potential conflicts of interest, please visit our website at williamblair.com. Next up, we have NIAX from ...

Connect Biopharma Holdings (CNTB) Conference June 04, 2025 09:00 AM ET Speaker0 Barry, floor is yours. Thank you, Robert. Appreciate the opportunity to be here, and welcome, everyone. We'll start with the usual forward looking statements. Please see our SEC filings for full description of risks. So I really appreciate the opportunity to talk about the new chapter in Connect Biopharma. I like to think of it as Connect two point zero. Last year, the Board made a decision to bring in a new management team, one ...

Summary of Quidel Ortho Conference Call Company Overview - Quidel Ortho was formed by the merger of Quidel and Ortho Clinical Diagnostics in May 2022, focusing on four major business areas: labs, transfusion medicine, point of care, and molecular diagnostics [5][6] - The company reported approximately $2.8 billion in revenue for the full year 2024, with North America contributing 58% of total revenues [6][7] Market Position and Growth Opportunities - The in vitro diagnostics market is valued at $50 billion, growing in the mid-single digits, with Quidel Ortho targeting segments worth approximately $20 billion [9] - The labs business generated $1.4 billion in revenue in 2024, representing about 50% of total revenue, and is expected to grow consistently [10] - The transfusion medicine business, excluding donor screening, generated $523 million in revenue in 2024, with low single-digit growth expected [12] - Point of care contributed $694 million in revenue in 2024, with mid-single-digit growth anticipated [13] - Molecular diagnostics revenue was $24 million in 2024, identified as a significant near-term growth opportunity [13] Strategic Initiatives - The company announced plans to acquire full ownership of Lex Diagnostics for approximately $100 million, aiming to enhance its product portfolio [14][15] - Discontinuation of the Savanna platform was decided due to unsatisfactory clinical trial results, allowing a focus on more promising technologies [15] - The Lex platform is expected to provide rapid and accurate testing, integrating well into existing workflows [16][17] Financial Performance and Cost Management - In Q1, Quidel Ortho achieved a 6% revenue growth, excluding COVID and donor screening, with a 450 basis point improvement in adjusted EBITDA [23] - Cost savings of over $100 million were identified in 2024, with an additional $30 million to $50 million expected in 2025 [22] - The company aims to reduce its net leverage ratio to 2.5 to 3.5 times while expanding margins [24][25] Future Outlook - The company reaffirmed its 2025 financial guidance, targeting mid to high 20s adjusted EBITDA margin [25] - Capital allocation will prioritize business needs, including menu expansion and molecular strategy, while focusing on cash generation and debt reduction [26] - Quidel Ortho is positioned for profitable growth with a strong value proposition and stable underlying business [27]

Summary of AvePoint (AVPT) FY Conference Call - June 04, 2025 Company Overview - AvePoint is the largest SaaS data governance and security player in the Microsoft Office cloud ecosystem, focusing on unstructured data, which constitutes 80% of all data [4][5] - The immediate addressable market is estimated at $19 billion, covering governance, risk, compliance, data replication, and protection [5][6] Core Business and Strategy - AvePoint operates a singular SaaS platform with 15 instances running in Microsoft Azure, GCP, and AWS, emphasizing a multi-cloud strategy [9][10] - The platform includes three major areas: resiliency (backup as a service), control (data governance), and modernization (data analytics, integration, migration) [11][13] - Resiliency accounts for over 50% of recurring revenue, while control is the fastest-growing suite due to AI deployments [11][13] - The company aims to reduce service revenue from 20% to under 10% to focus on recurring revenue streams [16] Market Position and Competitive Landscape - AvePoint differentiates itself by providing a vertical stack solution within the Microsoft ecosystem, unlike competitors like Commvault and Varonis, which take a horizontal approach [44][45] - The company serves a diverse customer base, with 53% of recurring revenue from companies with over 5,000 employees and 47% from small to medium-sized businesses [18] - The competitive landscape is described as complex, with multiple point competitors, but AvePoint maintains a unique position due to its comprehensive data management solutions [17][48] Financial Performance - Total ARR growth of 26% year-over-year, with net new ARR of $18.5 million, reflecting 85% year-over-year growth [24][25] - SaaS revenue increased by 34% on a constant currency basis, and total revenue rose by 25% [25] - Gross retention stands at 89%, and net retention is at 111%, with targets to improve these figures [27] - Operating margin is reported at just under 14.5%, with a strong start to the year [28] Growth Potential and Future Outlook - AvePoint aims for a long-term target of $1 billion in ARR with a 25% CAGR [21] - The company is focused on profitable growth, with improvements in gross margins from 72% to nearly 76% [35] - Capital allocation strategy includes investing in business growth, pursuing M&A opportunities, and share repurchases [39][40] Customer Engagement and Value Proposition - AvePoint emphasizes the importance of data governance and quality in the context of AI and security, positioning itself as an advocate for customers navigating multi-cloud environments [54][55] - The company has established a strong relationship with Microsoft, leveraging its position within the ecosystem while addressing customer needs for diverse data management solutions [52][56] Key Takeaways - AvePoint's diversified approach across industries and customer segments is a significant strength, allowing for scalability and resilience in a competitive market [30][61] - The company has successfully built a global organization with a focus on profitable growth, setting the stage for future expansion and innovation [62][63] - Continuous investment in technology and customer relationships is crucial for maintaining competitive advantage in the evolving landscape of data management and governance [40][65]

Dynatrace (DT) FY Conference June 04, 2025 09:00 AM ET Speaker0 Good to kick off? All right. Well, thanks, everyone, for joining here in person or listening over the webcast. Before we begin, my name is Jake Roberge. I am the research analyst here at William Blair that covers Dynatrace. And for a full list of our research disclosures, please visit our website at williamblair.com. Well, with that, really excited to have Rick McConnell, the chief executive officer of Dynatrace, Jim Benson, the chief financial ...

Dolby Laboratories (DLB) FY Conference June 04, 2025 09:00 AM ET Speaker0 All right. Good morning. Why don't we go ahead and get started. I'm Ralph Schackart, Internet Analyst here at William Blair. Thanks again for attending our Annual Growth Stock Conference. Today, we're really excited to have Kevin back from Dolby to give you an overview on the business. Just a quick overview of the company because I think it'll help level set. I've covered the company since the IPO which is a long time ago. And through ...

Blend Labs (BLND) FY Conference June 04, 2025 09:00 AM ET Speaker0 Perfect. Thank you, everyone. Good morning. My name is Dylan Becker. I'm the research analyst here at William Blair that covers Blend Labs. For all the necessary disclosures, can find those on williamblair.com. We're joined here today with Nima Gamsari, the CEO and founder of Blend. Nima, you for joining us. There's probably varying levels of familiarity to the story, Nima. If you don't mind providing kind of some context, background, kind o ...

Rivian Automotive (RIVN) 2025 Conference June 04, 2025 08:50 AM ET Speaker0 Alright. Welcome, everyone. We're about to kick off the second annual UBS Auto and Auto Tech Conference. Really pleased all of you can join us here today, in person and online. And to to kick the conference on, super excited to have with us, Rivian. We have, Founder and CEO, RJ Skirinj, with us, up on up on stage. Got a couple of their beautiful vehicles outside, so please take a take a look at those as well. So RJ, thanks for thank ...